# Tesaglitazar

| | |
|---|---|
| **Cat. No.:** | HY-17444 |
| **CAS No.:** | 251565-85-2 |
| **Molecular Formula:** | $C_{20}H_{24}O_7S$ |
| **Molecular Weight:** | 408.47 |
| **Target:** | PPAR |
| **Pathway:** | Cell Cycle/DNA Damage |
| **Storage:** | Powder -20°C 3 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with **$EC_{50}$**s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ. Tesaglitazar induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats[1]. |
| **$IC_{50}$ & Target** | EC50: 13.4 μM (rat PPARα), 3.6 μM (human PPARα), 0.2 μM (PPARγ)[1] |

## REFERENCES

[1]. Hellmold H, et al. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci. 2007 Jul;98(1):63-74.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA